Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.50 |
| ▸ | MPO | P05164 | 3/20 | 0.42 |
| ▸ | HTR1D | P28221 | 7/20 | 0.42 |
| ▸ | HTR1A | P08908 | 5/20 | 0.42 |
| ▸ | HTR1B | P28222 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337645 | 0.89 | LPL (0.42) | LPLLIPGMPOHTR1DHTR1A | |
| SCHEMBL12016746 | 0.86 | HTR1A (0.56) | MPOHTR1DHTR1AHTR1BHTR2A | |
| SCHEMBL758451 | 0.83 | CYP2D6 (0.49) | LPLLIPGMPOHTR1DHTR1A | |
| SCHEMBL25776268 | 0.82 | LPL (0.37) | LPLLIPGMPOHTR1DHTR1A | |
| SCHEMBL15897087 | 0.81 | ALDH1A1 (0.56) | LIPGHTR1DHTR1AHTR1B | |
| SCHEMBL1337551 | 0.79 | ATM (0.41) | LPLLIPG | |
| SCHEMBL15912503 | 0.78 | LPL (0.42) | LPLLIPGHTR2A | |
| SCHEMBL2422531 | 0.77 | NPC1 (0.48) | LPLLIPGHTR1DHTR1AHTR1B | |
| SCHEMBL23157343 | 0.76 | PRMT5 (0.54) | MPOHTR1DHTR1AHTR1B | |
| SCHEMBL22438423 | 0.75 | LPL (0.38) | LPLLIPGHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-2566847-B1 | NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS | ICOZEN THERAPEUTICS PVT LTD (IN) | 2018-11-07 | — | — | EP | disclosed |
| US-9758474-B2 | Immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-09-12 | — | — | US | disclosed |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | INCOZEN THERAPEUTICS PVT. LTD. (CH) | 2014-08-07 | — | — | US | disclosed |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | RHIZEN PHARMACEUTICALS SA (FR) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | LPL 2531/4885LIPG 1575/4885MPO 4072/4885 |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | LPL 768/4885LIPG 402/4885MPO 27/4885 |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | LPL 768/4885LIPG 402/4885MPO 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.